Hyperglycosylated hCG Drives Malignancy in Most or All Human Cancers: Tying All Research Together
DOI:
https://doi.org/10.6000/1927-7229.2018.07.01.3Keywords:
hCG, hyperglycosylated hCG, malignancy.Abstract
Objectives: Two forms of hCG are produced, the hormone hCG binding a luteinizing hormone/hCG joint receptor and the autocrine hyperglycosylated hCG binding a TGF-ß receptor. In pregnancy, hyperglycosylated hCG drives placental cell growth and invasion in implantation of pregnancy. It also blocks apoptosis. Human cancer cells steal the hCG ß-subunit gene and use hyperglycosylated hCG and its ß-subunit to drive malignancy. Here we examine research into hyperglycosylated hCG and its ß-subunit, and show that these molecules drive malignancy in most or possibly all human cancers.
Methods: Mouse monoclonal antibody B152was raised against intact hyperglycosylated hCG, batch C5. The antibody binds hyperglycosylated hCG and its ß-subunit but does not bind the hormone hCG or its subunits. Total hCG was measured using the Siemens Immulite hCG assay, hyperglycosylated hCG and its ß-subunit were measured using the antibody B152 assay.
Results: Eight independent center show that the hCG ß-subunit produced by cancers promotes malignancy, enhances cancer cell growth, cancer cell invasion and blockage of apoptosis in cancers. A study of 42 choriocarcinoma cases shows that percentage hyperglycosylated hCG exactly correlates with weekly doubling rate of cancer. It is concluded that hyperglycosylated hCG drive malignancy in this cancer. In a study with 7 separate cancers it is shown that increasing concentrations of hyperglycosylated hCG enhance all cancers. Increasing concentration of monoclonal antibody B152.
Hyperglycosylated hCG and its ß-subunit drives cancer growth, cancer invasion and blocks apoptosis in cancer cells. Antibody B152 suppressed cancer cell growth creating a non-malignant-like state (no growth, no invasion), with no cancer growth over a starting 70% confluency.
Conclusions: Choriocarcinoma is an example of cancer driven in malignancy by hyperglycosylated hCG, cancer aggression (weekly doubling rate) exactly correlating with percent hyperglycosylated hCG. In examining cancers, antibody B152 suppresses malignancy totally halting cancer growth in 7 of 7 cancer. This confirms that only the antigens, hyperglycosylated hCG and its ß-subunit drives malignancy in cancer cases.
References
Cole LA, Dai D, Leslie KK, Butler SA, Kohorn EI. Gestational trophoblastic diseases: 1. Pathophysiology of hyperglycosylated hCG-regulated neoplasia. Gynecol Oncol 2006; 102: 144-149.
Kovalevskaya G, Genbacev O, Fisher SJ, Cacere E, O’Connor JF. Trophoblastorigin Elliott MM, Kardana A, Cole LA. Carbohydrate and Peptide structure of the α- and β-subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinoma. Endocrine 1997; 7: 15-32. https://doi.org/10.1007/BF02778058
Elliott MM, Kardana A, Cole LA. Carbohydrate and Peptide structure of the α- and β-subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinoma. Endocrine 1997; 7: 15-32. https://doi.org/10.1007/BF02778058
Valmu L, Alfthan H, Hotakainen K, Birken S, Stenman UH. Site-specific glycan analysis of human chorionic gonadotropin beta-subunit from malignancies and pregnancy by liquid chromatography - electrospray mass spectrometry. Glycobiol 2006; 16: 1207-1218. https://doi.org/10.1093/glycob/cwl034
Cole LA. hCG and Hyperglycosylated hCG Carbohydrate Structures Corrected. J Glycobiol 2014; 3: 1000114.
Cole LA. The Minute Structural Difference between the Hormone hCG and the Autocrine Hyperglycosylated hCG. J Glycobiol 2017; in press. https://doi.org/10.4172/2168-958X.1000127
Butler SA, Ikram MS, Mathieu S, Iles RK. The increase in bladder carcinoma cell population induced by the free beta subunit of hCG is a result of an anti-apoptosis effect and not cell proliferation. Brit J Cancer 2000; 82: 1553-1556.
Berndt S, Blacher S, Munuat C, Detilleux J, Evain-Brion D, Noel A, Fournier T, Foidart JM. Hyperglycosylated human chorionic gonadotropin stimulates angiogenesis through TGF-ß receptor activation. FASEB J 2013; 12-213686.
Ahmud F, Ghosh S, Sinha S, Joshi SD, Mehta VS, Sen E. TGF-ß-induced hCG-ß regulates redox homeostasis in glioma cells. Molec Cellul Biochem 2015; 399: 105-112. https://doi.org/10.1007/s11010-014-2237-6
Cole LA, Khanlian SA, Kohorn EI. Evolution of the Human Brain, Chorionic Gonadotropin and Hemochorial Implantation of the Placenta: Origins of Pregnancy Failures, Preeclampsia and Choriocarcinoma. J Reprod Med 2008; 53: 449-557.
Cole LA. The evolution of the primate, hominid and human brain. Primatology 2015; 4: 100124.
Sasaki Y, Ladner DG, Cole LA. Hyperglycosylated hCG the source of pregnancy failures. Fertil Steril 2008; 89: 1871-1786. https://doi.org/10.1016/j.fertnstert.2007.03.010
Cole LA. Hyperglycosylated hCG and Pregnancy Failures. J Reprod Immunol 2012; 93: 119-122. https://doi.org/10.1016/j.jri.2012.01.001
Cole LA. Hyperglycosylated hCG drives malignancy in cancer cases. J Molec Oncol Res 2017; 1: 53-63.
Gillott DJ, Iles RK, Chard T. The effects of beta-human chorionic gonadotrophin on the in vitro growth of bladder cancer cell lines. Br J Cancer 1996; 73: 323-326. https://doi.org/10.1038/bjc.1996.56
Devi GR, Oldenkamp JR, London CA, Iversen PL. Inhibition of human chorionic ß-subunit modulates the mitogenetic effect of c-myc in human prostate cancer cells. Prostate 2002; 53: 200-310. https://doi.org/10.1002/pros.10151
Cole LA, Dai D, Leslie KK, Butler SA, Kohorn EI. Gestational trophoblastic diseases: 1. Pathophysiology of hyperglycosylated hCG-regulated neoplasia. Gynecol Oncol 2006; 102: 144-149.
Jankowska A, Gunderson SI, Warchol JB. Reduction of hCGß subunit expression by modified U1 snRNA caused apoptosis in cervical cancer cells. Molec Cancer 2008; 7: 26-29. https://doi.org/10.1186/1476-4598-7-26
Li D, Wen X, Ghali L, et al. hCG β expression by cervical squamous carcinoma-in vivo histological association with tumour invasion and apoptosis. Histopathol 2008; 53: 147-55. https://doi.org/10.1111/j.1365-2559.2008.03082.x
Guo X, Liu G, SchauerI G, et al. Overexpression of the β Subunit of Human Chorionic Gonadotropin Promotes the Transformation of Human Ovarian Epithelial Cells and Ovarian Tumorigenesis. Am J Pathol 2011; 179: 1385-1393. https://doi.org/10.1016/j.ajpath.2011.05.018
Kawamaja F, Nishihara H, Homma S, et al. Chorionic gonadotropin-ß modulates epithelial-mesenchymal transition in colorectal carcinoma metastasis. Am J Path 2018; 188: 207-215.
Birken S, Krichevsky A, O’Connor J, Schlatterer J, Cole LA, Kardana A, Canfield R. Development and characterization of antibodies to a nicked and hyperglycosylated form of hCG from a choriocarcinoma patient. Endocrine J 1999; 10: 137-144. https://doi.org/10.1385/ENDO:10:2:137
Siler-Khodr TM, Khodr GS, Valenzuela G, Rhode J. Gonadotropin-releasing hormone effects on placental hormones during gestation: I. Alpha-human chorionic gonadotropin, human chorionic gonadotropin and human chorionic somatomammotropin.Biol Reprod 1986; 34: 245-54. https://doi.org/10.1095/biolreprod34.2.245
Mathialagan N, Rao AJ. Gonadotropin releasing hormone (GnRH) stimulates both secretion and synthesis of human chorionic gonadotropin (hCG) by first trimester human placental minces in vitro. Biochem Int 1986; 13: 757-65.
Iwashita M, Kudo Y, Shinozaki Y, Takeda Y. Gonadotropin-Releasing Hormone Increases Serum Human Chorionic Gonadotropin in Pregnant Women. Endocrine J 1993; 40: 539-544. https://doi.org/10.1507/endocrj.40.539
Leung PC, Cheng CK, Zhu XM. Multi-factorial role of GnRH-I and GnRH-II in the human ovary. Molec Cellul Endocrinol 2003; 202: 145-153. https://doi.org/10.1016/S0303-7207(03)00076-5
Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 1999; 20: 1247-1262. https://doi.org/10.1016/S0196-9781(99)00130-8
Lennon FE, Moss J, Singleton PA. The ψ-opiod receptor in cancer progression: Is there a direct effect? Anaesthesiology 2012; 100: 940-945. https://doi.org/10.1097/ALN.0b013e31824b9512
Cole LA, Butler SA. Cole LA, Butler SA. B152 anti-hyperglycosylated human chorionic gonadotropin free β-Subunit. A new, possible treatment for cancer. J Reprod Med 2015; 60:13-20.